PGT-A can shorten the path to a live birth and reduce miscarriage rates for some patients, but the evidence consistently shows it does not improve cumulative live-birth rates for everyone, and it may actively harm outcomes for younger patients with good-quality embryos. Whether the test is worth it depends heavily on your age, how many embryos you produce, and what you are trying to optimize for. The science behind this question is more contested than most fertility clinics let on, and the answer has shifted as better-designed trials have come in over the past decade.
What PGT-A Actually Does
PGT-A screens IVF embryos for chromosomal abnormalities before transfer. The procedure involves removing a small number of cells from the trophectoderm (the outer layer of a blastocyst that eventually forms the placenta) and analyzing them for missing or extra chromosomes. Embryos with the correct chromosome count are labeled “euploid” and prioritized for transfer, while those with abnormal counts are typically set aside. The technology has evolved considerably over three decades, moving from early methods that could only check a handful of chromosomes to modern sequencing platforms that evaluate all 23 pairs.1PubMed. From innovation to practice: evaluating the evidence for preimplantation genetic testing for aneuploidy
The rationale sounds straightforward: chromosomal abnormalities in embryos are common and increase with maternal age. They are a leading cause of implantation failure, miscarriage, and conditions like Down syndrome. By identifying and avoiding aneuploid embryos, PGT-A should, in theory, improve the odds with each transfer. And in fact, it does improve per-transfer success rates. The controversy is about whether it improves your overall chances of taking home a baby from a given egg retrieval cycle, and whether the testing itself introduces problems of its own.
Where the Evidence Favors PGT-A
The clearest benefit of PGT-A shows up in patients 38 and older. A 2025 study found that patients in this age group who used PGT-A had a higher live-birth rate over one year compared to those who skipped it (about 51% versus 36%), and they reached that outcome faster.2Fertility and Sterility. The impact of preimplantation genetic testing for aneuploidy on time to live birth in in vitro fertilization A network meta-analysis of randomized trials likewise found that PGT-A improved live-birth rates in women over 35, with a roughly 29% relative increase.3Journal of Assisted Reproduction and Genetics. PGT-A: who and when? Α systematic review and network meta-analysis of RCTs
This makes biological sense. The rate of chromosomal errors in eggs rises steeply with age, meaning older patients tend to produce a higher proportion of aneuploid embryos.4PubMed Central. Impact of Maternal Age on Oocyte and Embryo Competence When a large share of your embryos carry abnormalities, selecting one with the right chromosome count before transfer avoids the heartbreak and lost time of transferring an embryo destined to fail. For older patients specifically, PGT-A also dramatically cut pregnancy loss rates. One study of women with advanced maternal age found that pregnancy loss dropped from about 23% without PGT-A to under 4% with it.5PubMed Central. Preimplantation Genetic Testing for Aneuploidy Improves Clinical, Gestational, and Neonatal Outcomes in Advanced Maternal Age Patients Without Compromising Cumulative Live-Birth Rate
PGT-A also reduces the number of transfers needed to achieve a pregnancy. For patients with more than one embryo, this translates to fewer failed transfers and fewer clinical miscarriages, which means less emotional strain and time in treatment, potentially shaving months off the process.6PubMed. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage When you consider that each failed transfer involves hormonal preparation, time off work, and the psychological toll of a negative result, that efficiency gain is real.
Where the Evidence Cuts Against PGT-A
For younger patients with good-quality embryos, the picture looks very different. The largest randomized controlled trial on this question, published in the New England Journal of Medicine, followed over 1,200 women and found that conventional IVF actually produced a higher cumulative live-birth rate than PGT-A (about 82% versus 77%). Among women with three or more good-quality blastocysts, skipping PGT-A was at least as effective as using it.7PubMed. Live Birth with or without Preimplantation Genetic Testing for Aneuploidy
That finding is reinforced by studies looking specifically at younger patients. In women under 35 with good prognoses, PGT-A did not improve live-birth rates or reduce miscarriage rates compared to transferring untested embryos.8PubMed. The role of preimplantation genetic testing for aneuploidy in a good prognosis IVF population across different age groups The same held true for women aged 35 to 37 in that study. And a randomized trial of young patients (35 and under) with at least two good-quality blastocysts found that transferring the best-looking euploid embryo produced no better results than transferring the best-looking untested embryo.9Prenatal Diagnosis. Single best euploid versus single best unknown-ploidy blastocyst frozen embryo transfers: a randomized controlled trial
The network meta-analysis that found benefits for women over 35 found no benefit at all in younger women.3Journal of Assisted Reproduction and Genetics. PGT-A: who and when? Α systematic review and network meta-analysis of RCTs Why? If you are young and producing mostly normal embryos, the test is more likely to discard a perfectly healthy embryo than to save you from a bad one. This is partly because younger patients have lower aneuploidy rates to begin with, and partly because of the test’s own limitations, which deserve their own discussion.
The Mosaicism Problem
One of the most significant complications in PGT-A is mosaicism, where an embryo contains a mix of chromosomally normal and abnormal cells. Mosaic embryos are detected at rates ranging anywhere from 2% to over 35% of tested embryos, depending on the laboratory and technology used.10PubMed Central. Parental and cell-division origin analysis to reduce false-positives in mosaic embryos for preimplantation genetic testing That enormous range alone signals a problem: labs cannot reliably tell whether they are seeing real mosaicism in the embryo or just noise introduced by the testing process itself.
This matters for two reasons. First, some embryos labeled “mosaic” may actually be fully normal. If a patient has limited embryos, discarding a mosaic one that was really healthy is a devastating error. Second, some mosaic embryos are genuinely capable of producing healthy babies, though at lower rates than euploid ones. The live-birth rate after transferring mosaic embryos is lower than after transferring euploid embryos (roughly 47% versus 59% in one analysis), but it is still far from zero.11PubMed Central. Rates of live birth after mosaic embryo transfer compared with euploid embryo transfer The clinical challenge is that current methods cannot reliably distinguish true mosaicism from artifacts introduced during biopsy and amplification.10PubMed Central. Parental and cell-division origin analysis to reduce false-positives in mosaic embryos for preimplantation genetic testing
How Accurate Is the Test?
PGT-A works by sampling a few cells from the outer shell of the embryo and extrapolating the chromosome status of the entire organism. When the result is clearly euploid or clearly aneuploid, the test is quite reliable: one study found a concordance rate of about 99.5% for euploid calls and 97% for aneuploid calls when comparing the biopsy to the inner cell mass (the part that actually becomes the baby).12PubMed Central. The reproducibility of trophectoderm biopsies in euploid, aneuploid, and mosaic embryos using independently verified next-generation sequencing (NGS): a pilot study Those are reassuring numbers for clear-cut results.
The trouble is with the gray zone. When the biopsy yields a mosaic result, the concordance between what the biopsy says and what the inner cell mass actually is drops to about 35%.12PubMed Central. The reproducibility of trophectoderm biopsies in euploid, aneuploid, and mosaic embryos using independently verified next-generation sequencing (NGS): a pilot study In other words, a mosaic call is more likely to be wrong than right when it comes to predicting what the developing fetus would actually look like chromosomally. A separate study found an overall concordance between biopsy sites and the inner cell mass of about 86 to 90%, regardless of where on the outer shell the cells were taken from, suggesting that abnormal cells can be scattered unpredictably across the embryo.13PubMed Central. Concordance between different trophectoderm biopsy sites and the inner cell mass of chromosomal composition measured with a next-generation sequencing platform
Adding another layer of uncertainty: the same embryo can receive different classifications depending on which lab analyzes it, what sequencing platform is used, and where the thresholds for calling a result “normal” versus “mosaic” versus “abnormal” are set. There are no universal standards for these thresholds, so transfer decisions can hinge on analytical choices rather than biological reality.14Human Reproduction. Navigating uncertainty in PGT-A: aligning analytical, biological, and clinical evidence
The Biopsy Itself Is Not Risk-Free
Removing cells from a developing embryo is an invasive procedure, and there is growing evidence it may carry consequences. The biopsy removes five to ten cells from the trophectoderm, which is the precursor to the placenta. A comprehensive review noted that mathematical modeling suggests the broad application of PGT-A leads to a net loss of potentially viable embryos, possibly because of biopsy-related damage.15PubMed Central. Obstetric, neonatal, and child health outcomes following embryo biopsy for preimplantation genetic testing Some studies have found associations between trophectoderm biopsy and abnormal placentation conditions, including pre-eclampsia and preterm birth. There is also evidence that biopsied blastocysts produce lower levels of a key pregnancy hormone (hCG) in proportion to how many cells were removed, hinting at disrupted placental development.15PubMed Central. Obstetric, neonatal, and child health outcomes following embryo biopsy for preimplantation genetic testing
Mouse model research has explored whether the mechanical stress of removing trophectoderm cells could disrupt placental and fetal development in surviving embryos, including through changes in how genes are regulated.16Human Reproduction. Trophectoderm biopsy of blastocysts following IVF and embryo culture increases epigenetic dysregulation in a mouse model These are early signals rather than established harms, but they raise questions that the field is still working to answer. A Danish national registry study comparing children born after PGT to those born after standard IVF/ICSI found no significant differences in rates of asthma, allergic disorders, or other early childhood health conditions, which is reassuring for the time being.17PubMed Central. Preimplantation genetic testing and child health: a national register-based study
The Frozen Transfer Wrinkle
PGT-A requires freezing all embryos while the biopsy results come back, which means every transfer is a frozen embryo transfer (FET) rather than a fresh one. This introduces an indirect complication. Several studies have found that frozen transfers performed with programmed (hormone-mediated) cycles carry a higher risk of pre-eclampsia and other hypertensive disorders compared to natural-cycle frozen transfers. One multicenter cohort study found the odds of pre-eclampsia were roughly 2.7 times higher in programmed FET cycles versus natural ones.18PubMed. Programmed frozen embryo transfer cycle increased risk of hypertensive disorders of pregnancy: a multicenter cohort study in ovulatory women
The leading theory centers on the corpus luteum, a temporary structure in the ovary that forms after ovulation and secretes hormones important for vascular adaptation in early pregnancy. In programmed cycles, ovulation is suppressed, so no corpus luteum forms. The absence of its hormonal output, particularly relaxin, may compromise the cardiovascular changes a pregnant body needs to make.19PubMed. Frozen Embryo Transfer and Preeclampsia Risk This risk is not unique to PGT-A, but PGT-A guarantees a frozen transfer, and many clinics default to programmed FET cycles because they are easier to schedule. Patients who are aware of this issue can discuss natural-cycle FET options with their clinic.
The Cost Equation
PGT-A typically adds several thousand dollars to an IVF cycle, and in many countries it is not covered by insurance. Whether that cost makes financial sense depends, again, on age and embryo count. One cost-effectiveness analysis using data from over 158,000 IVF cycles in the United States found that for patients under 35, PGT-A was associated with both worse outcomes and higher costs. At ages 35 to 38, PGT-A led to more cumulative births but at higher cost. Starting at age 39, PGT-A became cost-effective from the patient’s perspective.20PubMed. The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: an analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles
For patients with more than one embryo available, a separate analysis found that PGT-A saved between $931 and $2,411 overall, depending on how many embryos were screened, because it reduced the number of paid transfer cycles needed.6PubMed. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage The savings came not from higher live-birth rates but from avoiding the cost of failed transfers and miscarriages. For patients with only one or two embryos to test, the upfront cost of PGT-A is harder to justify since there may be nothing to “select” among.
What Professional Guidelines Actually Say
Despite how commonly PGT-A is offered, professional bodies remain cautious. The American Society for Reproductive Medicine identifies advanced maternal age as the only indication for PGT-A in its committee opinion. Some other societies also endorse it for recurrent implantation failure and recurrent miscarriage, and a few extend the indication to male factor infertility.21PubMed Central. Diverging guidelines and consensus statements on preimplantation genetic testing for aneuploidy: indications and strategies reviewed No major society recommends PGT-A universally for all IVF patients, yet surveys of fertility clinic websites show that nearly half advertise it, and very few mention the possibility that it might not help or could have drawbacks.22Reproductive Biomedicine Online. The prevalence, promotion and pricing of three IVF add-ons on fertility clinic websites
That disconnect between professional guidance and commercial practice is one of the most uncomfortable aspects of PGT-A. The test generates revenue for clinics and testing laboratories, and it appeals to patients who understandably want to do everything possible to succeed. But informed consent requires knowing that the evidence does not support universal use, particularly for younger patients with a reasonable embryo supply.
The Emotional Dimension
The decision to use PGT-A often carries a psychological weight that gets underplayed in clinical discussions. Qualitative research with PGT users found that many felt unprepared for the possibility of getting no transferable embryos after testing and wanted more attention given to the potential stages of failure throughout the procedure. The need for emotional support was a recurring theme.23PubMed Central. The decision-making process, experience, and perceptions of preimplantation genetic testing (PGT) users Getting results that label all your embryos as abnormal is a uniquely devastating experience, especially given the accuracy limitations discussed earlier. Some of those “abnormal” embryos might have led to healthy pregnancies if transferred. That uncertainty is hard to sit with.
Ethical concerns also surface for some patients. About 30% of people considering preimplantation genetic testing reported ethical conflicts around the process, including discomfort with embryo selection and disposal.24PubMed Central. Patients’ preimplantation genetic testing decision-making experience: an opinion on related psychological frameworks These are not trivial concerns, and they rarely get airtime in a busy consultation where the focus is on logistics and statistics.
Non-Invasive Alternatives on the Horizon
One of the most active areas of research aims to eliminate the biopsy entirely. Non-invasive PGT-A (niPGT-A) analyzes cell-free DNA that embryos shed into the culture medium they grow in, rather than removing cells directly. An early study found an overall concordance of about 82% between this non-invasive approach and standard biopsy results.25PubMed Central. Embryonic Cell-free DNA in Spent Culture Medium: A Non-invasive Tool for Aneuploidy Screening of the Corresponding Embryos However, a more recent and carefully validated study painted a less optimistic picture: the total concordance rate was about 64%, with a sensitivity for detecting aneuploidy of only 57%.26PubMed Central. Non-invasive preimplantation genetic testing for aneuploidy using cell-free DNA in blastocyst culture medium
At those accuracy levels, non-invasive testing is not ready to replace the biopsy-based method, but the concept is sound and the technology is improving. If it can be refined to reliably screen embryos without touching them, it would eliminate biopsy-related damage and make PGT-A less of a high-stakes gamble for patients with few embryos. For now, niPGT-A remains a research tool rather than a clinical option.
Chromosomal Errors Are Not Just an “Older Patient” Problem
There is a common assumption that aneuploidy is primarily a concern for women in their late thirties and beyond. While the rate does climb with age, the biology is more nuanced than that. Chromosomal abnormalities affect more than 40% of eggs in women at both ends of the reproductive age spectrum, including very young women.27PubMed Central. Origins and mechanisms leading to aneuploidy in human eggs The difference is that younger women typically produce more eggs per cycle, so even if a meaningful fraction are abnormal, there are enough normal ones that the body (or the embryologist) can find a winner without genetic screening. This is exactly why PGT-A shows little benefit in younger, good-prognosis patients: nature’s own selection process through implantation and early development is already filtering out most aneuploid embryos, just less efficiently than a lab test.
The situation changes when a younger patient produces very few embryos, or has experienced repeated unexplained losses. In those cases, the calculus shifts, because the usual abundance that makes PGT-A unnecessary is not present. Professional guidelines reflecting this nuance recommend PGT-A for recurrent miscarriage regardless of age.21PubMed Central. Diverging guidelines and consensus statements on preimplantation genetic testing for aneuploidy: indications and strategies reviewed
How Children Born After PGT-A Are Doing
For families who have already used PGT-A or are weighing the decision, long-term child health data matters. A national register-based study from Denmark compared children born after PGT to those born after standard IVF or ICSI and found similar rates of early childhood conditions, including asthma, allergic disorders, and a range of rare diagnoses like cerebral palsy and autism spectrum disorders.17PubMed Central. Preimplantation genetic testing and child health: a national register-based study Broader reviews of children conceived through assisted reproduction have found that when singleton pregnancies are considered separately, health outcomes are generally comparable to those of children conceived without medical help.28PubMed Central. Long-term health of children conceived after assisted reproductive technology These are reassuring findings, though follow-up periods are still relatively short given how recently modern PGT-A methods came into wide use.